Zileuton: A New Therapy for Asthma or Just the First of a New Class of Drugs?

National Heart, Lung, and Blood Institute. Global initiative for asthma. Global strategy for asthma management and prevention, NHLBI/WHO workshop report. National Institutes of Health Publication #95-3659, 1995: 2–8, 40–6.

Djukanovic R Wilson JW Britten KM Wilson SS Walls AF Roche WR . Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145: 669–74.

Wenzel SE Fowler AA III Schwartz LB . Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am Rev Respir Dis 1988; 137: 1002–8.

Bousquet J Chanez P Lacoste JY Barneon G Ghavanian N Enander I . Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033–9.

Corrigan CJ Haczku A Gemou-Engesaeth V Doi S Kikuchi Y Takatsu K . CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Am Rev Respir Dis 1993; 147: 540–7.

Holtzman MJ . Arachidonic acid metabolism. Implications of biological chemistry for lung function and disease. Am Rev Respir Dis 1991; 143: 188–203.

Laitinen LA Laitinen A Haahtela T Vilkka V Spur BW Lee TH . Leukotriene E₄ and granulocytic infiltration into asthmatic airways. Lancet 1993; 341: 989–90.

Corrigan CJ Kay AB . T cells and eosinophils in the pathogenesis of asthma. Immunol Today 1992; 13: 501–7.

Wenzel SE Kamada AK . Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann Pharmacother 1996; 30: 858–64.

Israel E Fischer AR Rosenberg MA Lilly CM Callery JC Shapiro J . The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–51.

Meltzer SS Rechsteiner EA Johns MA Cohn J Bleecker ER . Inhibition of exercise-induced asthma by zileuton, a 5-lipoxygenase inhibitor (abstract). Am J Respir Crit Care Med 1994; 149: A215.

Lehnigk B Rabe KF Hirst RS Carpentier PJ Magnussen H . Effect of ABT-761, a 5-lipoxygenase inhibitor, on exercise-induced bronchoconstriction in patients with bronchial asthma (abstract). Am J Respir Crit Care Med 1995; 151: A376.

Manning PJ Watson RM Margolskee DJ Williams VC Schwartz JI O'Byrne PM . Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D₄-receptor antagonist. N Engl J Med 1990; 323: 1736–9.

Makker HK Lau LC Thomson HW Binks SM Holgate ST . The protective effect of inhaled leukotriene D₄ receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147: 1413–8.

Reiss TF Bronsky E Hendeles L Hill J Harman E Guerreiro D . MK-0476, a potent leukotriene (LT) D₄ receptor antagonist, inhibits exercise-induced bronchoconstriction in asthmatics at the end of a once daily dosing interval (abstract). Am J Respir Crit Care Med 1995; 151: A377.

Anderson SD Seale JP Rozea P Bandler L Theobald G Lindsay DA . Inhaled and oral salbutamol in exercise-induced asthma. Am Rev Respir Dis 1976; 114: 493–500.

Wenzel SE Larsen GL Johnston K Voelkel NF Westcott JY . Elevated levels of leukotriene C₄ in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990; 142: 112–9.

Hui KP Taylor IK Taylor GW Rubin P Kesterson J Barnes NC . Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46: 184–9.

Taylor IK O'Shaughnessy KM Fuller RW Dollery CT . Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337: 690–4.

Findlay SR Barden JM Easley CB Glass M . Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89: 1040–5.

Rasmussen JB Eriksson LO Margolskee DJ Tagari P Williams VC Andersson KE . Leukotriene D₄ receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992; 90: 193–201.

Hendeles L Davison D Blake K Harman E Cooper R Margolskee D . Leukotriene D₄ is an important mediator of antigen-induced bronchoconstriction: attenuation of dual response with MK-571, a specific LTD₄ receptor antagonist (abstract). J Allergy Clin Immunol 1990; 85: 197.

Friedman BS Bel EH Buntinx A Tanaka W Han YH Shingo S . Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993; 147: 839–44.

Cockcroft DW Murdock KY . Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987; 79: 734–40.

Wenzel SE Trudeau JB Kaminsky DA Cohn J Martin RJ Westcott JY . Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995; 152: 897–905.

Anthracite R . FDA medical officer review of zileuton presented at the FDA Pulmonary/Allergy Drugs Advisory Committee meeting on March 10, 1995. F-D-C Reports — The Pink Sheet 1995; 57: 3–6.

Israel E Rubin P Kemp JP Grossman J Pierson W Siegel SC . The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059–66.

Pedersen S Hansen OR . Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995; 95: 29–33.

Noonan M Chervinsky P Busse WW Weisberg SC Pinnas J deBoisblanc BP . Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152: 1467–73.

Sun J . FDA pharmacology/toxicology review of zileuton. Presented at the FDA Pulmonary/Allergy Drugs Advisory Committee meeting on March 10, 1995.

Abbott Leutrol labeling for asthma should recommend 10 follow-up visits during first year on therapy to assess liver toxicity. FDA Advisory Committee. F-D-C Reports — The Pink Sheet 1995; 57: 3–6.

Abbott's zileuton. F-D-C Reports — The Pink Sheet 1995; 57: 13.